Camrelizumab Combined With Bevacizumab and HAIC in Patients With Metastatic Liver Cancer Who Failed Standard Therapy
NCT05643417
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
80
Enrollment
OTHER
Sponsor class
Conditions
Metastatic Liver Cancer
Interventions
DRUG:
HAIC、Bevacizumab、Camrelizumab
Sponsor
Fudan University